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A High-Density Screen for Linkage in Multiple Sclerosis
International Multiple Sclerosis Genetics Consortium*
To provide a definitive linkage map for multiple sclerosis, we have genotyped the Illumina BeadArray linkage
mapping panel (version 4) in a data set of 730 multiplex families of Northern European descent. After the application
of stringent quality thresholds, data from 4,506 markers in 2,692 individuals were included in the analysis. Mul-
tipoint nonparametric linkage analysis revealed highly significant linkage in the major histocompatibility complex
(MHC) on chromosome 6p21 (maximum LOD score [MLS] 11.66) and suggestive linkage on chromosomes 17q23
(MLS 2.45) and 5q33 (MLS 2.18). This set of markers achieved a mean information extraction of 79.3% across
the genome, with a Mendelian inconsistency rate of only 0.002%. Stratification based on carriage of the multiple
sclerosis–associated DRB1*1501 allele failed to identify any other region of linkage with genomewide significance.
However, ordered-subset analysis suggested that there may be an additional locus on chromosome 19p13 that acts
independent of the main MHC locus. These data illustrate the substantial increase in power that can be achieved
with use of the latest tools emerging from the Human Genome Project and indicate that future attempts to sys-
tematically identify susceptibility genes for multiple sclerosis will have to involve large sample sizes and an asso-
ciation-based methodology.
Introduction
Familial clustering of multiple sclerosis (MIM 126200)
has been recognized for more than a century (Eichorst
1896) and has been carefully measured in several large
population-based studies (Sadovnick et al. 1988; Robert-
son et al. 1996; Carton et al. 1997). The increased risk
seen in the siblings of affected individuals compared with
the general population is a useful measure of the degree
of familial clustering, known as “ls” (Risch 1990). In
multiple sclerosis, this risk ratio has a value of ∼20,
which indicates that the lifetime risk of developing the
disease is 20 times greater for a sibling of an affected
individual than for an individual from the general popu-
lation. Supplementary epidemiological studies of twins
(Mumford et al. 1994; Willer et al. 2003), adoptees (Ebers
et al. 1995), conjugal pairs (Robertson et al. 1997), and
half siblings (Ebers et al. 2004) indicate that shared ge-
netic factors are at least partly responsible for the ob-
served familial clustering, whereas studies of migrants
(Dean et al. 1976) and concerning the month of birth
(Willer et al. 2005) confirm that environmental factors
are also important in the pathogenesis of the disease
(Hogancamp et al. 1997).
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Many candidate genes have been investigated, but, to
date, the only region of the genome that has clearly and
consistently shown evidence of association with the dis-
ease is the major histocompatibility complex (MHC) on
chromosome 6p21, where, in Northern Europeans, as-
sociation with the DR15 human leukocyte antigen (HLA)
haplotype (DRB1*1501-DQB1*0602) is a constant
finding (Jersild et al. 1972; Winchester et al. 1975; Comp-
ston et al. 1976; Olerup and Hillert 1991; Stewart et al.
1997; Haines et al. 1998). In the mid-1990s, it became
possible to complete systematic whole-genome screens
for linkage; to date, 11 such studies have been published
about multiple sclerosis (Ebers et al. 1996; Haines et al.
1996; Sawcer et al. 1996; Kuokkanen et al. 1997; Broad-
ley et al. 2001; Coraddu et al. 2001; A˚kesson et al. 2002;
Ban et al. 2002; Eraksoy et al. 2003; Hensiek et al. 2003;
Kenealy et al. 2004). These screens have all been based
on microsatellite marker sets with a density of approxi-
mately one marker every 10 cM. This design has long
been accepted as the optimal approach (Hauser et al.
1996). Although all of these screens have identified
regions of interest, none has demonstrated linkage with
genomewide significance, although each has shown
more allele sharing among affected individuals than
would have been expected by chance alone. A recent
meta-analysis of the available raw genotypes demon-
strated linkage that just reached genomewide signifi-
cance in the MHC region but found no significant link-
age outside the region, despite the inclusion of 1700
multiplex families (GAMES and Transatlantic Multiple
Sclerosis Genetics Cooperative 2003). Close inspection
of the quality of the data included in this meta-analysis
revealed worrying inadequacies: the average genotyping
International Multiple Sclerosis Genetics Consortium: MS Linkage Screen 455
Table 1
Number of Markers per Chromosome
CHROMOSOME
NUMBER OF MARKERS
PER CHROMOSOME BY SAMPLE
Fulla Datab Qualityc Finald
1 478 472 444 396
2 475 471 454 377
3 398 395 377 319
4 296 291 273 246
5 312 309 296 252
6 410 408 390 334
7 285 284 272 230
8 260 259 246 212
9 205 204 195 176
10 248 246 228 196
11 229 223 203 177
12 285 281 261 222
13 187 184 163 145
14 210 206 189 158
15 201 199 190 150
16 197 195 175 145
17 159 154 134 113
18 170 168 161 142
19 149 143 129 102
20 130 127 121 102
21 103 103 97 73
22 121 121 106 96
Pseudo-Xp 20 20 17 8
X 304 290 154 132
Pseudo-Xq 8 8 7 3
Y 18 12 0 0
Total 5,858 5,773 5,282 4,506
a The complete Illumina linkage panel (version 4).
b Markers that generated data in samples.
c Markers that generated quality data ( ) inGQ 1 0.7
198% of samples.
d Final set of markers (all pairs having ).2r ! 0.16
success rate was just 80%, and the average information
extraction was only 44%. Although the accuracy of
genotyping was not reported in the majority of these
studies, others have observed that error rates as low as
0.5%–1% are likely to hold only for good-quality mi-
crosatellites (Lathrop et al. 1983) and that higher rates
would be expected for many markers (Brzustowicz et
al. 1993). This level of inaccuracy is predicted to pro-
foundly limit the expected LOD score and thereby se-
riously reduce the power to detect linkage (Abecasis et
al. 2001a). In light of these inadequacies, we compared
existing data from five affected-sib-pair families in-
cluded in the original 1996 British genome screen with
those generated using a more extensively engineered
higher density set of microsatellite markers (Applied
Biosystems High Density Linkage Mapping Set) and
two high-density SNP-based mapping sets (Illumina
BeadArray linkage mapping panel [version 3] and the
Affymetrix GeneChip Human Mapping 10K array).
This pilot experiment indicated that the SNP-based sys-
tems offer considerable advantages for genotyping suc-
cess rate, information extraction, and—most impor-
tantly—genotyping accuracy (International Multiple
Sclerosis Genetics Consortium 2004). The value of an
accurate linkage map cannot be overstated. Demon-
stration of robust linkage has enabled the identification
of susceptibility genes in several complex diseases (Hori-
kawa et al. 2000; Hugot et al. 2001; Haines et al. 2005)
and thus makes a definitive linkage study desirable.
On the basis of concerns about the quality of the geno-
typing data included in previous linkage screens (which
are no better or worse than those performed for other
complex diseases) and the encouraging results from the
pilot study, we rescreened available families from four
of the populations (Australian, Scandinavian, British, and
American) with the Illumina BeadArray linkage mapping
panel (version 4).
Material and Methods
Markers and Maps
The Illumina BeadArray linkage mapping panel (ver-
sion 4) includes 5,858 markers (table 1). In our samples,
5,773 (98.5%) of these markers generated potentially
usable data that satisfied minimum Illumina quality stan-
dards. Of these markers, 17 were uninformative for link-
age: 5 were monomorphic in our samples and 12 were
Y-linked (included in the panel to confirm the sex of
typed samples). A further 474 markers were excluded,
since !98% of genotypes generated by these markers had
GenCall (as defined in the “Genotyping” section) scores
10.7 among those samples considered to be of acceptable
quality (see the “Samples and Families” section). None
of the remaining 5,282 quality markers showed deviation
from Hardy-Weinberg equilibrium (HWE) (the genotyp-
ing success rate and heterozygosity for each of these 5,282
markers are provided in data file 1 [online only]). Among
these 5,282 markers, there are 5,812 pairs of markers
separated by !500 kb. Among the 5,812 pairs, there were
1,168 in which the linkage disequilibrium (LD) was found
to have . Since simulation studies (Boyles et al.,2r  0.16
in press) have shown that there is little if any inflation of
linkage evidence when the LD between markers had
, this threshold was applied to our data, and2r ! 0.16
selected markers were removed until all pairs of markers
separated by !500 kb, consecutive and nonconsecutive,
had . In this exclusion process, we aimed to re-2r ! 0.16
move the minimum number of markers possible. In
regions of high LD, this invariably meant that all but one
of a cluster of markers showing LD with each other
needed to be excluded. In each instance, markers showing
the lowest heterozygosity were excluded first, except when
the difference in heterozygosity between a pair of markers
was !10% and the more heterozygous marker included
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Table 2
Population-Specific Breakdown of Families and Individuals
Population
No. of
Families
No. of
Individualsa
Affected
Individuals
(M:F)
Unaffected
Founders
(M:F)
Unaffected
Nonfounders
(M:F)
Australian 97 330 59:142 33:37 26:33
Scandinavian 165 475 140:215 26:54 18:22
British 298 1,023 186:428 107:159 65:78
American 170 864 128:297 92:110 121:116
a Numbers of individuals for whom DNA was available and typed
Table 3
Demographic Features of Affected Individuals
POPULATION
AVERAGEa
RR
(%)
SP
(%)
PP
(%)
Age
(years)
Disease Duration
(years) EDSS
Australian 53.6 15.8 3.5b 64 24 12
Scandinavian 49.5 19.1 4.7 49 32 19
British 45.0 15.7 4.5 57 28 15
American 45.3 15.4 5.5 62 34 4
a EDSS p Expanded Disability Status Scale; RR p Relapse Re-
mitting; SP p Secondary Progressive; PP p Primary Progressive.
b The EDSS was not determined for these patients; instead, the av-
erage “disease steps” measure is shown (Hohol et al. 1999).
more than three Mendelian inconsistencies, in which case,
the genotyping error rate was considered to “trump” the
heterozygosity, and the more error-prone marker was re-
moved. In total, 776 markers were excluded from the
5,282 quality typed markers. Multipoint linkage analysis
was thus based on a total of 4,506 markers; all these
markers had an average genotyping success rate (for qual-
ity genotypes with GenCall scores 10.7) of 99.7% and
an average heterozygosity of 44.6% (only 23 markers
have a heterozygosity of !5%). When consecutive marker
pairs separated by !2 Mb were considered, only six ad-
ditional pairs had , and all these had .2 2r 1 0.16 r ! 0.44
It is therefore unlikely that residual LD has contributed
significantly to the background-allele sharing.
All the markers included in the linkage-mapping panel
(version 4) have been ordered and placed on the physical
map (build 34) and have had genetic coordinates interpo-
lated from the deCODE map (Kong et al. 2002). Markers
unresolved on the genetic map were given an arbitrary
separation of 0.01 cM. Among the 4,506 markers in-
cluded in the multipoint linkage analysis, the average
interval between consecutive markers is 0.82 cM, there
are no intervals of 110 cM, and 71% of intervals are
!1 cM.
Samples and Families
At the inception of this project, 2,923 individuals from
780 families were identified and considered. To monitor
and assure experimental variables, such as plate orien-
tation, and to provide the opportunity to test genotyping
reproducibility, inter- and intraplate duplicate genotyp-
ing was performed. Further duplicate genotyping was
also performed to obtain data from as many samples as
possible when the amount of available DNA was mini-
mal (see below). In total, genotyping of the linkage panel
markers was attempted for 3,417 samples. Of these sam-
ples, 13% (446) failed to genotype, with most (404) of
these failures occurring in whole-genome amplification
(WGA)–derived DNA (see the “WGA” section). The in-
cluded duplicate genotyping ensured that only 83 indi-
viduals had no sample that yielded genotypes. However,
since some of the individuals who failed to genotype were
affected, 41 families became uninformative for linkage
(because they had fewer than two successfully typed
affected individuals). Among the remaining 739 fami-
lies, comprising 2,754 typed individuals, 21 individuals
yielded !98% quality genotypes among the 5,282 good-
quality markers and were therefore also excluded. After
the exclusion of these lower-quality samples, a further
nine families became uninformative for linkage, and eight
families were reduced in size but were still informative.
From the five largest multigenerational families, 24 typed
individuals had to be excluded to ensure that the “bit”
parameter for these families did not exceed 19, the larg-
est value we were able to successfully analyze with this
version of MERLIN (Center for Statistical Genetics) (Abe-
casis et al. 2002).
In conclusion, 2,692 individuals (from 730 multi-
plex families) were ultimately included in the analysis
reported here—1,595 affected individuals (513 males;
1,082 females), 618 unaffected founders (258 males; 360
females), and 479 other unaffected relatives (230 males;
249 females). Families were drawn from four white popu-
lations (Australian, Scandinavian, British, and Ameri-
can), each of which had been previously screened for
linkage and either is Northern European or has Northern
European ancestry (table 2). The included families over-
lap substantially (70%) with those previously studied,
but 216 new families not previously screened are also
included. A breakdown of the demographic features of
the affected individuals is shown in table 3. Together,
the 730 families provide 1,002 affected-relative pairs,
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Table 4
Breakdown of Affected Relative Pairs by Population
POPULATION
NO. OF AFFECTED-RELATIVE PAIRS
Sibling
Half
Sibling Cousin Parent-Child Avuncular
Australian 68 5 16 2 8
Scandinavian 193 1 4 24 5
British 307 6 6 8 3
American 262 2 28 23 31
including 830 sib pairs, 14 half-sib pairs, 54 cousin pairs,
57 parent-child pairs, and 47 avuncular pairs; a break-
down by population is shown in table 4.
Ten individuals (all with DNA derived from cell lines)
showed significant loss of heterozygosity on one or, at
most, two chromosomes. These individuals were not in-
cluded in the analysis of the corresponding chromosomes.
Informed consent was provided by all individuals in-
volved in this study, and all affected individuals satisfy
standardized diagnostic criteria (Poser et al. 1983; Good-
kin et al. 1991; McDonald et al. 2001).
Allele Frequencies
By analyzing families from four populations together
as a single data set, we have tacitly assumed that these
are all drawn from the same homogenous population
(Northern European). To test this assumption, we cal-
culated Wright’s F statistic ( ), which measures the ex-FST
tent to which observed heterozygosity falls below that
which would be expected if all studied families had the
same genetic background. Employing heterozygosity and
allele frequency estimates derived from the full 730-fami-
ly data set using the PEDSTATS and MERLIN programs
(Center for Statistical Genetics) and averaging across all
4,506 markers, we found an value of 0.0019, whichFST
indicates a modest degree of population substructure (dif-
ference in the genetic background of the included fami-
lies), equivalent to that seen in older cohorts of the ho-
mogeneous Icelandic population (Helgason et al. 2005).
We then used the MERLIN program (Center for Statis-
tical Genetics) (Abecasis et al. 2002) to estimate sepa-
rately the allele frequencies among the founders in each
of the four populations for each of the 4,506 indepen-
dent markers. After Bonferroni correction, no marker
showed statistically significant difference in allele fre-
quency across the four populations. The average differ-
ence in the frequency of an allele between any two popu-
lations was only 3.6%, an amount that would not be
expected to significantly influence the results of linkage
analysis. In keeping with the four populations included
in the screen having a common genetic background, the
extent of difference in the estimated allele frequency was
found to be highly dependent on the number of samples
typed from each compared population. The smaller the
sample size used to estimate an allele frequency, the
greater the variance in the resultant estimate. Thus, be-
tween the American and British populations, there are
only 15 markers (0.3%) that showed a difference of
110% in allele frequency, whereas, between the Austra-
lian and Scandinavian populations, 361 markers (8.0%)
showed such a difference. Similarly, the frequency of
DR15 carriage among the typed founders from the four
populations did not show any statistically significant
difference.
For each marker in the linkage panel, Illumina pro-
vided ethnic subgroup–specific allele frequencies. For
whites, these frequencies were based on the genotyping
of 82 unrelated CEPH individuals. When we compared
these CEPH frequencies with those estimated from the
founders in our total set of 730 families, we found no
statistically significant differences after Bonferroni cor-
rection. Repeating the linkage analysis with use of the
CEPH allele frequencies rather than those derived from
the data itself did not produce any substantial change
in the results (the average change in the multipoint LOD
score was just 0.01, the greatest increase was just 0.21,
and the greatest reduction was just 0.30), which confirms
that our analysis is robust to modest misspecification of
allele frequencies.
Genotyping
Each individual provided a venous blood sample. Cell
lines were established from 390 individuals, and the DNA
used in this screen was extracted from a growth of these
lines. In the remaining individuals, DNA was extracted
directly from blood by use of standard methods. In some
cases, additional DNA was generated by WGA (see the
“WGA” section).
Each sample included in the analysis was genotyped
in four highly multiplexed assays containing up to 1,536
markers (SNPs) per tube. The assay products from these
were hybridized to high-density, bead-based microarrays
and were imaged on a submicron-resolution scanner. This
work was performed by the Illumina BeadLab service
facility in San Diego. The Illumina genotyping system is
fluorescence based, with one color specifying the first
allele (A) and a second color specifying the second allele
(B). Homozygous samples (AA or BB) therefore generate
a signal exclusively/predominantly in the corresponding
single color only, whereas heterozygous samples (AB) gen-
erate a signal in both colors. Since samples vary in their
performance, each marker produces three clusters of re-
sults within color-signal space, one for each genotype.
The tighter and more distinct the three different clusters
are, the more accurate the genotyping. As part of the
Illumina genotyping process, a quality measure known
as a “GenCall score” is determined for each genotype.
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This metric measures how close a genotype is to the
centre of the cluster of other samples assigned the same
genotype, as compared with the centers of the clusters
for the two other genotypes. This metric varies from 0
to 1, such that the higher the value, the more reliable
the genotype. A sample giving a signal close to the center
of a cluster that is tight and distinct from the other two
clusters will have a high GenCall score.
Genotyping data from the class II HLA gene DRB1
was generated using several different typing methods with
varying resolution. To maintain consistency across data
sets, we thus coded the HLA-DRB1 locus in terms of
the presence or absence of the DRB1*1501 allele (the
multiple sclerosis–associated allele). These data were
available for 2,448 (91%) of the individuals.
WGA
For 456 individuals, the total amount of DNA avail-
able was less than the minimum recommended for the
Illumina system; therefore, for each of these, we pro-
duced additional DNA by WGA with use of the Mo-
lecular Staging REPLI-g kit, in accordance with the manu-
facturer’s recommended conditions (Dean et al. 2002).
WGA was performed more than once for some individ-
uals, so that, in total, genotyping was attempted for 508
samples of WGA-derived DNA. Since initial results with
these samples were disappointing, we also attempted
genotyping in residual genomic DNA, when possible.
Among these 456 individuals, typing in residual genomic
DNA was attempted for 401, so that just 55 individuals
had genotyping attempted only in WGA-derived DNA.
Only 104 of the 508 WGA-derived DNA samples
yielded usable genotypes. As expected, the likelihood that
genotypes could be generated from WGA-derived DNA
correlated with the starting concentration of genomic
DNA used in the production reaction: the mean starting
concentration was 5.9 ng/ml in the samples that failed
to genotype and 17.4 ng/ml in those that worked. The
104 successfully typed WGA-derived DNA samples pro-
vided genotypes for 100 individuals, 4 of whom were
successfully genotyped in duplicate.
Duplicate Genotyping
In total, 138 individuals were successfully genotyped
in duplicate, and 5 individuals were successfully geno-
typed in triplicate, providing 148 independent compari-
sons (1854,000 duplicate genotypes). Among these com-
parisons, there were only 688 genotypes that were dif-
ferent, and, in each instance, only one allele differed.
Since each genotype includes two alleles and was typed
twice, our results indicate a crude error rate of 0.02%
(i.e., 688 alleles in error of alleles854,000# 2# 2
called). When we considered the GenCall scores asso-
ciated with the erroneous genotypes, we observed that
67% of the 688 errors involved genotypes with a Gen-
Call score of !0.7, whereas only 5.7% of all genotypes
had GenCall scores below that threshold. Similarly, con-
sideration of the genotyping call rate (a crude surrogate
for quality) among the markers associated with errone-
ous genotypes revealed that 63% of the error genotypes
occurred in the 46 markers with genotyping call rates
!99%. To balance the amount of usable data with its
accuracy, we set the following stringent but arbitrary
thresholds. We chose to include only genotypes with a
GenCall score 10.7, among which we would expect the
crude error rate to be !0.01%. We also chose to exclude
all markers with a genotyping call rate of !98% for
quality genotypes (i.e., those with GenCall scores 10.7)
among the quality samples and to exclude all samples
with a call rate of !98% for quality genotypes (GenCall
10.7) among quality markers. These thresholds resulted
in the exclusion of 474 markers and 21 samples (as
described above).
Among the 148 comparisons, 52 involved only ge-
nomic DNA, 92 involved both WGA-derived and ge-
nomic DNA, and 4 involved only WGA-derived DNA.
The crude error rate in the 52 comparisons that were
based on only genomic DNA (0.012%) was less than
half that seen among the 96 comparisons involving at
least one WGA-derived sample (0.025%). In view of this
evidence, for greater reliability, genotypes derived from
genomic samples were included in preference to those
derived from WGA-derived samples when both were
available, except when the genotyping success rate in the
genomic sample was substantially less than that from
the WGA-derived DNA.
Across the 730 families typed for the 4,506 markers
finally included in the multipoint analysis (112 million
genotypes), only 254 Mendelian inconsistencies were ob-
served, which indicates a final approximate error rate of
only 0.002%.
Statistical Analysis
The pedigree structure for each included family was
confirmed by comparing the expected and observed
identity-by-state (IBS) allele sharing for each pair of re-
lated individuals with use of the Graphical Relationship
Representation (GRR) program (Center for Statistical
Genetics) (Abecasis et al. 2001b). Pairs of individuals
were also compared across families to exclude any dupli-
cation. Marker heterozygosity, genotyping success rate,
and evidence of deviation from HWE were determined
using the PEDSTATS program (Center for Statistical Ge-
netics) (Wigginton et al. 2005).
LD between autosomal markers was tested using the
Haploview program (which considers both consecutive
and nonconsecutive pairs) (Barrett et al. 2005) and be-
tween X-linked markers, by use of the PDTPHASE pro-
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gram (which considers only consecutive pairs) (UN-
PHASED Web site) (Dudbridge 2003). The PDTPHASE
program (UNPHASED Web site) was also used to test
for evidence of association with disease, after removal
of Mendelian inconsistencies with use of the PedCheck
program (O’Connell and Weeks 1998).
Since there is no currently available software capable
of combining information from the pseudoautosomal
and sex-linked regions of the X chromosome to enable
a single integrated linkage analysis, we treated the sex-
linked and two pseudoautosomal regions as three inde-
pendent chromosomes. However, the pseudoautosomal
regions could not be treated as straightforward auto-
somes, since, at the transition point from the sex-linked
to pseudoautosomal regions, the sharing of the pater-
nally derived chromosome is determined exclusively by
the sex of the pair considered, the fragment being shared
for same-sex siblings but unshared for opposite-sex sib-
lings. Since multiple sclerosis affects females more often
than males, paternally derived pseudoautosomal alleles
are expected to show excess sharing. Analysis of this re-
gion is further complicated by the extreme difference in
the sex-specific recombination rates, which are substan-
tially higher in the paternally derived haplotype. There-
fore, in each pseudoautosomal region, linkage analysis
was confined to the maternally derived chromosomes.
Apart from the pseudoautosomal regions on the X
chromosome, multipoint nonparametric linkage analysis
was performed using the MERLIN (Center for Statistical
Genetics) and MINX (Merlin in X) programs (Abecasis
et al. 2002), with default settings and allele frequencies
estimated from the founders. In this linkage analysis,
improbable genotypes were first removed using the pro-
gram’s wipe function (Abecasis et al. 2002); again, de-
fault settings were accepted. In total, 5,692 improbable
genotypes were removed from 2,888 marker family com-
binations. Single-point LOD scores are provided in data
file 1 (online only).
MERLIN’s simulation function (Center for Statistical
Genetics) was used to empirically estimate the signifi-
cance of the proportion of the genome that showed ex-
cess allele sharing. Twenty whole-genome replicates of
the screen (460 chromosomes) were analyzed under the
null hypothesis of no linkage. The proportion of the ge-
nome with a positive LOD score was then determined
in each whole-genome replicate.
In the pseudoautosomal regions, we restricted analysis
to a single randomly chosen sib pair from each of the
simple nuclear families ( ) and used the MAP-np 646
MAKER/SIBS program (MIT Genome Center) (Kruglyak
and Lander 1995) to determine the maximum likelihood
identical-by-descent allele sharing in each case. Con-
sidering the sex-concordant ( ) and -discordantnp 375
( ) pairs separately, we then counted the numbernp 271
of pairs sharing and not sharing the maternal haplotype
and tested any difference using a x2 test. On the short
arm, there was no excess sharing, whereas, on the long
arm, there was nominally significant excess maternal
haplotype sharing ( ). As expected, there wasPp .001
no significant difference between the sharing observed
in the pseudoautosomal regions and that measured in
the adjacent X-linked regions; results for the pseudoauto-
somal regions are not included in the figure.
The potential influence of transmission-ratio distor-
tion (TRD) was sought using the GENEHUNTERsad
program (Kruglyak et al. 1996; Lemire et al. 2004). This
program incorporates the novel allele-sharing test sta-
tistic Sad, which depends not only on excess allele sharing
between affected relatives but also on the lack of allele
sharing between phenotypically discordant relatives. The
Sad statistic is therefore substantially more resistant to
the presence of TRD than the analogous Whittemore and
Halpern (1994) Spairs statistic. The difference in the non-
parametric linkage (NPL) scores obtained using these
two allele-sharing test statistics (NPL_ Spairs and NPL_
Sad) thus provides a measure of the evidence for the pres-
ence of TRD. Since GENEHUNTER (MIT Genome Cen-
ter) (Kruglyak et al. 1996) performs an exact multipoint
test for linkage, memory requirements limit the number
of markers that can be included in any one analysis,
especially within larger families. As a result of this limit,
the genome was analyzed on the basis of 98 overlapping
fragments, with an average of 54 markers per fragment.
To estimate the ls attributable to individual linkage
peaks, we measured the maximum likelihood zero allele-
sharing probability in the affected sib pairs from the 646
simple nuclear families, using the MAPMAKER/SIBS
program (MIT Genome Center) (Kruglyak and Lander
1995).
Two approaches were used to examine the data for
the presence of loci interacting with the known DRB1*
1501 association; each approach was applied twice,
once favoring those carrying the associated DRB1 allele
(1501) and then again favoring those not carrying the
associated allele (1501). In the first approach, the data
were stratified on the basis of the presence or absence
of the DRB1*1501 allele in the affected individuals by
appropriately recoding the affection status prior to anal-
ysis with MERLIN (with default setting as described
above) (Center for Statistical Genetics). In this recoding
(stratified) analysis, 409 families were informative for
linkage in the 1501 analysis (i.e., included at least two
affected individuals, each carrying at least one DRB1*
1501 allele), and 187 families were informative for link-
age in the 1501 analysis (i.e., included at least two
affected individuals who each carry no DRB1*1501 al-
leles). This approach ignores affected-relative pairs that
are discordant for DRB1*1501 status and allows pairs
from the same family to be included in each subset. In
the second approach, we performed an ordered-subset
460
Figure 1 Multipoint nonparametric linkage analysis performed using MERLIN (Center for Statistical Genetics). The figure includes one
graph for each chromosome; the length of the X-axis is proportional to the genetic length of the corresponding chromosome, and the Y-axis
scale is 0–3 in each case, except on chromosome 6, where the scale is 0–12.
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Table 5
Top Results from the Linkage Analysis
Chromosome MLS
Sibling
Allele Sharing
(%) ls
6p21 11.66 58.5 1.51
17q23 2.45 53.8 1.18a
5q33 2.18 54.0 1.19a
20p12 1.83 54.0 1.09a
3p26 1.74 53.4 1.16a
a Since the evidence for linkage at these loci is
not statistically robust, these estimates provided
upper limits for the size of effects attributable to
underlying susceptibility factors (Terwilliger et al.
2002).
analysis (OSA [Duke Center for Human Genetics]) (Hau-
ser et al. 2004) of the data, using the chromosome 6
family-specific maximum LOD score (MLS) within the
2-cM region spanning HLA-DRB1 as the covariate. In
this method, families are ranked according to the co-
variate, then sequentially combined so that subset-spe-
cific LOD scores can be recalculated (using GENE-
HUNTER plus [MIT Genome Center] [Kruglyak et al.
1996; Kong and Cox 1997]) at each point in the genome.
The ordered subset of families giving the greatest total
LOD score is thereby identified. This procedure was per-
formed twice, first ranking the families from highest to
lowest covariate value (the “1501” analysis) and then
from lowest to highest (the “1501” analysis). Since each
OSA (Duke Center for Human Genetics) involves a con-
siderable degree of multiple testing, empirical methods
are employed to judge the nominal significance of any
evidence of linkage seen in an ordered subset. Only
regions with subsets involving 110% of the total number
of families and with nominal significance of !5% are
reported (a more extensive list of results is available in
data file 2 [online only]).
Neither of the approaches described above could be
employed on chromosome 6, because of the inevitable
presence of linkage with the DRB1 gene. On this chro-
mosome, we tested only those 44 families in which no
typed individuals were positive for DRB1*1501. This
ultra-negative group of families is modest in number and
therefore lacks power but has the virtue of being essen-
tially independent of DRB1*1501.
Results
The results of multipoint nonparametric linkage analysis
are shown in figure 1. Unequivocal linkage is demon-
strated in the region of the MHC. Two other regions
show suggestive evidence of linkage: chromosomes
17q23 and 5q33. The most negative LOD score seen
anywhere in the genome is only 0.79, and overall
63.9% of the genome (outside chromosome 6) showed
a positive LOD score rather than the expected 50%.
Simulation studies under the null hypothesis of no link-
age demonstrated that the mean proportion of the ge-
nome with a positive score is 49.7% (SD 6.7%). None
of the replicate screens showed an excess of positive
scores greater than that observed in the actual screen,
which indicates an empirical significance of !5%. This
bias in favor of positive scores confirms, again as in
previous studies, more allele sharing than would be ex-
pected by chance. Table 5 summarizes the results from
the six highest MLS peaks. In each case, the extent of
allele sharing observed among affected siblings was used
to estimate the ls attributable to individual loci (Risch
1990). This screen confirms that, outside the MHC re-
gion under the assumption of complete homogeneity,
there are no loci with .l 1 1.2s
To determine the extent to which the observed linkage
peaks and background excess sharing might reflect un-
derlying TRD, we compared the NPL scores obtained
using the Spairsand Sad allele-sharing test statistics (see the
“Material and Methods” section). The observed differ-
ence ranged from0.80 to0.82 and averaged0.02.
The overall excess of score seen with the Spairs statistic
as compared with the Sad statistic suggests that at least
some part of the excess background-allele sharing ob-
served in the screen might be due to the presence of
TRD. However, there does not seem to be any region
in which the presence of TRD has exerted a major effect.
The Spairs statistic gave higher scores than did the Sad
statistic at each of the peaks listed in table 5, but these
inflations were modest; increases were only 0.32, 0.25,
0.45, 0.18, and 0.51 at chromosomes 6p21, 17q23,
5q33, 20p12, and 3p26, respectively. In short, there is
no evidence to support the argument that TRD is re-
sponsible for the linkage peaks observed in this study.
Stratification of the data for the associated HLA allele
DRB1*1501 did not uncover any new region of statis-
tically significant linkage. The highest LOD score seen
in the 1501 group of families is 2.18 on chromosome
5q33, which corresponds exactly to the third-highest
LOD score seen in the total analysis and thereby sug-
gests that the locus may exert its effects in concert with
DRB1. The highest LOD score in the 1501 group is
1.61 on chromosome 2p25, in a region in which no
linkage was seen in the combined analysis. The pro-
portion of the genome providing positive LOD scores
is inflated in both the 1501 (62.5%) and 1501 (60.9%)
analyses. No evidence of linkage was seen in the analysis
of 1501 families on chromosome 6; in the HLA region,
the LOD score was just 0.17.
In the OSA (Duke Center for Human Genetics), we
found four additional regions of potential interest—chro-
mosome 12q24 (nominal ) emerging from thePp .008
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OSA that builds on families with evidence of linkage
in the HLA region and chromosomes 19p13 (nominal
), 1q43 (nominal ), and 7q21 (nomi-Pp .001 Pp .032
nal ) emerging from the OSA that builds onPp .033
families not showing evidence of linkage in the HLA
region. After appropriate correction for the number
of genomic regions considered, only the chromosome
19p13 result remains interesting, just reaching the cor-
rected 5% significance threshold.
Each of the 5,282 markers passing quality standards
was also tested for evidence of association with disease;
after appropriate Bonferroni correction, no significant
association was identifiable. The marker rs575208 from
chromosome 1p13 showed the most-extreme evidence
for association, with a corrected P value of 0.06. Im-
portantly, none of the markers from the MHC region
showed evidence of association with the disease, which
indicates that the LOD score in this region has not been
inflated by allelic association with the disease. Nominal
(uncorrected) P values for each marker are provided in
data file 1 (online only).
Discussion
To our knowledge, we have completed the largest and
most powerful linkage screen ever performed for multi-
ple sclerosis. The genotyping data included is highly ac-
curate and virtually complete, making false-negative re-
sults from a lack of genome coverage extremely unlikely.
Unequivocal linkage is demonstrated in the MHC re-
gion, and suggestive linkage is identified on chromosomes
17 and 5. OSA (Duke Center for Human Genetics) iden-
tifies a further locus on chromosome 19 that acts inde-
pendent of HLA.
Although linkage to the MHC region is expected, given
its established association with multiple sclerosis, the sub-
stantially greater LOD score attained in this screen com-
pared with previous studies (Ebers et al. 1996; Haines
et al. 1996; Sawcer et al. 1996; Kuokkanen et al. 1997;
Broadley et al. 2001; Coraddu et al. 2001; A˚kesson et
al. 2002; Ban et al. 2002; Eraksoy et al. 2003; Hensiek
et al. 2003; Kenealy et al. 2004) convincingly illustrates
the increased power of this new study. In the individual
10-cM microsatellite-based screens, the MHC region
has never shown linkage with genomewide significance
(Ebers et al. 1996; Haines et al. 1996; Sawcer et al.
1996; Kuokkanen et al. 1997; Broadley et al. 2001;
Coraddu et al. 2001; A˚kesson et al. 2002; Ban et al.
2002; Eraksoy et al. 2003; Hensiek et al. 2003; Kenealy
et al. 2004). Even in the meta-analysis of these micro-
satellite-based screens (GAMES and Transatlantic Mul-
tiple Sclerosis Genetics Cooperative 2003), the LOD
score in the MHC region only just reached the genome-
wide significance threshold. Since the present study in-
cludes approximately the same number of families as
the meta-analysis (GAMES and Transatlantic Multiple
Sclerosis Genetics Cooperative 2003), the substantially
greater LOD score from the MHC region confirms the
additional power provided by the greater information
extraction and genotyping accuracy of the new study.
Furthermore, the allele sharing observed in the MHC
region in our screen is consistent with what would be
predicted from the known frequency and risk attrib-
utable to the DRB1*1501 haplotype, indicating that if
secondary risk loci lie within the MHC region they are
unlikely to exert more than a very modest additional
effect on risk. The absence of linkage among those fami-
lies uninfluenced by DRB1*1501 is further evidence
against a substantial second locus in or near the MHC
region. The possibility of additional risk loci within the
MHC region is a popular hypothesis (Ligers et al. 2001;
Marrosu et al. 2001; Harbo et al. 2004), but we have
been unable to find any linkage evidence to support this
hypothesis.
Although the non-MHC peaks of linkage observed
in our study fail to reach genomewide statistical signifi-
cance as defined by Lander and Kruglyak (1995), they
provide invaluable information concerning the magni-
tude of effects likely to be attributable to multiple scle-
rosis–susceptibility genes. Given that the predicted ef-
fect sizes calculated from these linkage peaks are ex-
pected to be overestimates (Terwilliger et al. 2002), it
is reasonable to conclude that the calculated ls values
shown in table 5 provide a robust upper limit to the
size of effect attributable to genuine loci. This result has
substantial implications for future research into the ge-
netic aspects of this disease.
In consideration of the results of this screen, it is im-
portant to remember that the power of linkage analysis
falls rapidly as the effects attributable to individual genes
decline (Risch and Merikangas 1996). One corollary of
this limited resolution is that failure to detect linkage
does not exclude the existence of genes with more-mod-
est effects below the resolution provided by the screen.
Therefore, it should not be concluded that the failure
of this study to demonstrate statistically significant link-
age outside the MHC region indicates that no such genes
exist.
A number of confounding effects could have pre-
vented the detection of linkage in this study. It seems
reasonable to expect that susceptibility to multiple scle-
rosis is genetically heterogeneous and equally reason-
able to expect that the relative importance of individual
genes will differ between populations. In this setting,
combining families from different backgrounds may ac-
tually dilute rather than strengthen the evidence of link-
age. In our screen, however, we have been able to con-
firm that there is little difference in the genetic back-
ground of the four populations considered, as expected
from their genealogically common ancestry. This con-
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cordance makes it unlikely that there will be much dif-
ference between the genetic factors that determine sus-
ceptibility in each of the subpopulations and suggests
that much more is likely to have been gained from the
increased power provided by the greater number of fami-
lies included.
Following a similar line of reasoning, it seems logical
to suggest that individuals developing multiple sclerosis
due to risk alleles at one set of loci might show pheno-
typic differences from those developing their disease sec-
ondary to risk conferred by a different set of suscepti-
bility loci. Although multiple sclerosis shows extreme
variability in its phenotype, the evidence of familial clus-
tering of particular phenotypic features is modest (Bar-
cellos et al. 2002), and, at the moment, there is no
robust manner in which to select subgroups of patients
that might be genetically more homogeneous, even
though these subgroups would be expected to include
more penetrant alleles. On the other hand, it is ines-
capable that rare variants from multiple loci (extensive
locus heterogeneity) could account for a significant part
of the genetically determined susceptibility to multiple
sclerosis, in which setting, our study would have little
power to identify linkage to the individual contributory
loci.
How to appropriately correct for multiple testing is an
unresolved issue. Throughout this work, we have em-
ployed an ultraconservative approach and have applied
crude Bonferroni correction. This procedure maximizes
specificity but reduces power. Although the genetic
model underlying susceptibility to multiple sclerosis is
unknown, it seems reasonable to expect that it will in-
volve a spectrum of relatively common risk alleles ex-
erting only modest effects as well as less-common risk
alleles with more pronounced effects (Wang et al. 2005).
The significant excess of sharing seen in the genome
outside chromosome 6 confirms that other non-MHC
genes exist but have been missed by the limited power
of this approach.
This screen provides the most definitive linkage map
currently available for multiple sclerosis. Inspection of
this map indicates that future studies attempting to iden-
tify genetic factors influencing the development of this
disease will need to rely on association-based methods
and must involve large patient cohorts. A review of the
available genetic literature about multiple sclerosis
shows that few studies met these criteria. A lack of
concordance in the results from underpowered studies
is entirely expected and provides little if any guidance
as to which loci have been excluded and which are
potentially relevant. In short, our screen indicates that
all logical candidates will need to be reevaluated with
more powerful studies.
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